Clinical DevelopmentLiquidia presented the first detailed data from its 48-week open-label safety study for L606, showing no treatment-related discontinuations, no severe adverse events, and only mild, transient cough in a small subset of patients.
Phase 3 TrialsLiquidia shared new details on Re-Spire, a planned global Phase 3 pivotal trial in PH-ILD, which will enroll 344 patients across 20+ countries.
Product InnovationThe core innovation is the liposomal technology and its salt-sensitive sustained-release properties, enabling enhanced drug deposition in the lower airways while limiting upper-airway exposure, supporting a favorable tolerability profile.